NAPM/GPhA Merger Likely Ends Generic User Fees Push In 107th
This article was originally published in The Tan Sheet
Executive Summary
The merger agreement between the National Association of Pharmaceutical Manufacturers and the Generic Pharmaceutical Association likely means generic drug user fees will not be a focal point of the PDUFA reauthorization process.
You may also be interested in...
GPhA In Transition: Milanese Steps In As Hatch/Waxman Hill Debate Looms
A transition in the Generic Pharmaceutical Association's leadership comes as pressure for congressional action on Hatch/Waxman reform increases
GPhA In Transition: Milanese Steps In As Hatch/Waxman Hill Debate Looms
A transition in the Generic Pharmaceutical Association's leadership comes as pressure for congressional action on Hatch/Waxman reform increases
GPhA In Transition: Milanese Steps In As Hatch/Waxman Hill Debate Looms
A transition in the Generic Pharmaceutical Association's leadership comes as pressure for congressional action on Hatch/Waxman reform increases